Global AndrogenReplacement Therapy Market, by Product Type (Testosterone Creams/Gels,Testosterone Patches, Testosterone Injections, Testosterone Implants, andTestosterone Tablets/Capsules/Gums), by Active Ingredient Type (Testosterone,Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, andTestosterone Cypionate), by Distribution Channel (Hospital Pharmacies, RetailPharmacies, and Online Pharmacies), andby Region (North America, Latin America, Europe, Asia Pacific, Middle East, andAfrica), is estimated to be valued at US$ 1,965.5 million in 2021 and isexpected to exhibit a CAGR of 7.8% during the forecast period (2021-2028).
Product approval by regulatoryauthorities is expected to drive growth of the global androgen replacementtherapy market during the forecast period. For instance, in October 2018,Antares Pharma received the U.S. FDA approval for XYOSTED (testosteroneenanthate) injection. XYOSTED is the first U.S. FDA approved subcutaneoustestosterone enanthate product for once-weekly, at-home self-administrationwith an easy-to-use, single dose, disposable QuickShot auto injector. XYOSTEDhas been approved in three dosage strengths- 50 mg, 75 mg, and 100 mg, and isindicated for testosterone replacement therapy in adult males for conditionsassociated with a deficiency or absence of endogenous testosterone.
Key players are focused ondevelopment and launch of new advanced androgen replacement therapies in themarket, which is expected to contribute significantly to the androgenreplacement therapy market growth. For instance, in October 2018, PerrigoCompany plc. announced the launch of an AB-rated generic version of AndrogelTopical Gel, 1.62% (20.25mg testosterone/1.25g packet, 40.5mg testosterone/2.5gpacket, and 20.25mg/1.25g actuation pump).
Global Androgen ReplacementTherapy Market - Impact of Coronavirus (COVID – 19) Pandemic
COVID-19 outbreak was firstreported on December 31, 2019 in Wuhan, China. According to the Coronavirus(COVID-19) Weekly Epidemiological Update by the World Health Organization, over146 million cases and 3.1 million deaths due to coronavirus (COVID-19) werereported up till April 25th, 2021 across the globe.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3787
The coronavirus (COVID-19)pandemic and lockdown in various countries across the globe has impacted thefinancial status of businesses in all sectors. The private healthcare sector isone of the sectors which has been majorly affected by the pandemic. Thelockdown in various countries have created an economic burden on the privatehealthcare sector. Healthcare providers are facing challenges with regards tomanpower, equipment, consumables, and other resources to ensure safety ofpatients with other diseases, and declining outpatient’s visits among others.
Moreover, the pandemic hasnegatively impacted the development, production, and supply of drugs, andaffected growth of the healthcare segment of various companies across theglobe. This has led to closure of industrial establishments, exceptmanufacturing of essential commodities and disruption in supply chain ofproducts. The COVID-19 pandemic has affected the economy in three main ways: 1)by directly affecting the production and demand; 2) by creating disruptions indistribution channels; and 3) through its financial impact on companies andfinancial markets.
Supply chain and manufacturingactivities in India, China, the U.S., and others have been disrupted due tolockdowns. Whereas, countries such as Thailand, Indonesia, Singapore, andothers are facing problems with transportation of drugs and medications. TheCOVID-19 pandemic is expected to slightly disrupt the R&D activities in theandrogen replacement therapy market.
Browse 39 Market Data Tables and22 Figures spread through 191 Pages and in-depth TOC on Global AndrogenReplacement Therapy Market, by Product Type (Testosterone Creams/Gels,Testosterone Patches, Testosterone Injections, Testosterone Implants, andTestosterone Tablets/Capsules/Gums), by Active Ingredient Type (Testosterone,Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, andTestosterone Cypionate), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies,and Online Pharmacies), and by Region (North America, Latin America, Europe,Asia Pacific, Middle East, and Africa).
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/androgen-replacement-therapy-market-3787
Several market players arefocused on acquisition of commercial rights to expand their product portfolioand gain maximum share of market. For instance, in April 2016, Aytu BioScience,Inc., announced the exclusive licensing of its third commercial-stage urologyproduct in just 11 months, with the execution of a long-term, exclusive licenseagreement with an affiliate of Acerus Pharmaceuticals Corporation for the U.S.commercial rights to Natesto (testosterone) Nasal Gel. Natesto is the first and only nasalformulation of testosterone approved by the U.S. Food and Drug Administration(FDA), as a replacement therapy for men diagnosed with hypogonadism.
Key Takeaways of the AndrogenReplacement Therapy Market:
The global androgen replacementtherapy market is expected to exhibit a CAGR of 7.8% over the forecast period(2021-2028), owing to growth in potential markets, especially in Europe. While,North America accounted for the major market share over the forecast period(2021 -2028).
Market players are indulged inlaunching of products, which is expected to drive growth of the global androgenreplacement therapy market over the forecast period. For instance, in April2020, Xiromed LLC launched Testosterone Gel 1.62% Metered Dose Pump(20.25mg/1.25g pump actuation), an AB-rated generic version of AndroGel 1.62%.AndroGel 1.62% is indicated for replacement therapy in males for conditionsassociated with a deficiency or absence of endogenous testosterone.
Some of the major playersoperating in the global androgen replacement therapy market include AbbVie,Inc., Bayer AG, Endo Pharmaceuticals, Plc., Eli Lilly and Company, Kyowa KirinInternational Plc., Novartis International AG, Pfizer Inc., ClarusTherapeutics, Inc., Perrigo Company Plc, Acerus Pharmaceuticals Corporation,Sawai pharmaceutical Co., Ltd., Reddy's Laboratories, Sun PharmaceuticalIndustries Ltd., and Simple Pharma.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3787
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
